US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

The global sleep tech market size was valued at USD 20,522.0 million in 2024 and is expected to grow from USD 23,054.4 ...

However, when cortisol levels stay high for extended periods due to chronic stress, lack of proper rest, or underlying health ...

Effectively managing workplace stress requires a proactive approach. One fundamental strategy is task prioritisation and ...

If you’re constantly feeling tired or sleepy, it might be time to see a professional. Experts highlight conditions that could ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

The US Food and Drug Administration (FDA) has accepted for priority review Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

Migraine affects over 1 billion people worldwide, with women being three times more likely to suffer than men. Around 90% of ...

The new technology has sensors that help people identify breathing patterns, snoring, teeth grinding and sleep apnea.

Groundbreaking research shows how your sleep patterns may be silently increasing your diabetes risk, with night owls facing the highest threat.

Stress is a global health crisis, but adaptogenic herbs like Rhodiola and Holy Basil offer a natural solution. Rhodiola and ...